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SUMMARY 
Cycle inhibiting factors (Cifs) are virulence proteins secreted by the 
type III secretion system of some Gram-negative pathogenic bacteria 
including Burkholderia pseudomallei. Cif is known to function to deamidate 
Nedd8, leading to inhibition of Cullin E3 ubiquitin ligases (CRL) and 
consequently induction of cell cycle arrest. Here I show that Cif can function 
as a potent activator of MAPK/ERK signaling without significant activation of 
other signaling pathways downstream of receptor tyrosine kinases. 
Importantly, I found that the ability of Cif to activate ERK is dependent on its 
deamidase activity, but independent of Cullin E3 ligase inhibition. This 
suggests that apart from Nedd8, other cellular targets of Cif-dependent 
deamidation exist. I provide evidence that the mechanism involved in Cif-
mediated ERK activation is dependent on recruitment of the Grb2-SOS1 
complex to the plasma membrane. Further investigation revealed that Cif 
modifies the phosphorylation status of SOS1 in a region containing the 
CDC25-H and proline-rich domains. It is known that prolonged Cullin E3 
ligase inhibition leads to cellular apoptosis. Therefore, I hypothesise that ERK 
activation is an important mechanism to counter the pro-apoptotic effects of 
Cif. Indeed, I show that Cif-dependent ERK activation promotes 
phosphorylation of the pro-apoptotic protein Bim, thereby conferring a pro-
survival signal. In summary, I identified a novel deamidation-dependent 
mechanism of action of the B. pseudomallei virulence factor Cif/CHBP to 
activate MAPK/ERK signaling. ERK activation may counter the pro-apoptotic 
effects of Cif and hence promote bacterial pathogenicity. My study also 
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demonstrates that bacterial proteins such as Cif can serve as useful 
molecular tools to uncover novel aspects of mammalian signaling pathways. 	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1.1 Burkholderia pseudomallei: The causative agent of melioidosis 
Burkholderia pseudomallei is a Gram-negative, environmental 
saprophyte that is commonly found in stagnant waters and muddy soils in 
endemic regions including many parts of Southeast Asia, Northern Australia, 
as well as other tropical regions (Currie et al., 2000; Leearasamee, 2000; 
White, 2003). Besides these primary ecological niches, B. pseudomallei is 
also capable of surviving within a wide range of hosts such as amoebae, 
nematodes, plants as well as many mammalian species including humans 
(Inglis et al., 2000; Gan et al., 2002; Holden et al., 2004; Lee et al., 2010; 
Sprague and Neubauer, 2004).  
Infection with this opportunistic pathogen usually occurs via respiratory, 
percutaneous or oral routes, and causes a potentially life-threatening disease 
known as melioidosis (Dharakul and Songsivilai, 1999). Individuals with 
underlying predisposing risk factors associated with compromised immune 
responses, of which the most predominant is diabetes mellitus, are more 
susceptible to B. pseudomallei infection (White, 2003; Cheng and Currie, 
2005; Wiersinga et al., 2006). Although the clinical manifestation and outcome 
of melioidosis vary widely, the most prevalent symptom is severe pulmonary 
distress, which can progressively lead to septicaemia and death (Asche, 
1991; Suputtamongkol et al., 1994; Wiersinga et al., 2006). At present, the 
mortality rate resulting from B. pseudomallei infection remains exceptionally 




antibiotics and there is currently no licensed vaccine available (Dance, 1991; 
Chaowagul, 2000; Ngauy et al., 2005). 
B. pseudomallei is a highly versatile intracellular bacterium that is 
adept at invading and surviving in different tissues and cell types (Jones et al., 
1996; Galyov et al., 2010). It is well established that upon exposure, B. 
pseudomallei invades the mammalian host cells, escapes from the 
phagosomes, replicates within the host cytosol, and spreads from cell to cell 
by inducing cell fusion through multi-nucleated giant cell formation (Stevens et 
al., 2002; Burtnick et al., 2008). In order to mediate these processes, B. 
pseudomallei utilises a number of virulence mechanisms including the type III 
and type VI secretion systems (Stevens et al., 2004; Warawa and Woods, 
2005; Cornelis, 2006; Jani and Cotter, 2010). These secretion systems are 
highly specialised machineries that allow the bacterium to dock on the host 
cell plasma membrane and translocate effector proteins across this surface 
membrane into the host cell cytosol or to directly inject effector proteins from 
within the host cytosol. The delivered effector proteins function to alter host 
cellular responses to establish an infection.  
Of the hundreds of effector molecules of the type III secretion system 
identified to date, many have been reported to frequently target host cell 
nuclear factor κappaB (NF-κB) and mitogen-activated protein kinase (MAPK) 
signaling pathways (Mota and Cornelis, 2005). This is not surprising because 
both the NF-κB and MAPK signaling pathways function as host defense 
mechanisms against invading pathogens. As such, interference with these 




response and support its replication and survival within the host cells. 
 
1.2 Cycle Inhibiting Factor is a virulence effector of B. pseudomallei 
Among the wide array of virulence effector proteins, Cycle inhibiting 
factors (Cifs) are one group of bacterial virulence proteins that are secreted by 
the type III secretion system of Gram-negative bacterial pathogens (Jubelin et 
al., 2009; Yao et al., 2009).  Cif was initially discovered in enteropathogenic 
Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC) and 
subsequently in four other pathogenic or symbiotic bacteria: Burkholderia 
pseudomallei, Yersinia pseudotuberculosis, Photorhabdus luminescens and 
Photorhabdus asymbiotica (De Rycke et al., 1997; Jubelin et al., 2009). 
Upon injection into host cells, Cif is known to inhibit host cell cycle 
progression at both G1/S and G2/M phase transitions. This halt in cell cycle 
progression may play a role in promoting bacterial colonization of the host 
cells. It has been shown that the cell cycle arrest is induced as a result of 
stabilization of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 
(hereafter referred to as p21 and p27) (Samba-Louaka et al., 2008; Jubelin et 
al., 2010; Cui et al., 2010). Cellular concentrations of the cell cycle inhibitors 
p21 and p27 are normally tightly regulated via ubiquitination by cullin RING E3 
ubiquitin ligases (CRLs). Ubiquitinated p21 and p27 are then targeted to the 
26S proteasome for degradation (Tsvetkov et al., 1999; Carrano et al., 1999; 
Sutterlüty et al., 1999). Cif has been shown to inhibit CRL function, leading to 
the accumulation of p21 and p27 (Figure 1). Another mechanism through 




CRL-dependent IκB degradation (Figure 2). As a result, NF-κB activation 
upon bacterial infection is prevented (Cui et al., 2010). 
 
Figure 1. Cif inhibits Cullin E3 Ring ubiquitin ligase (CRL) function via 
deamidation of Nedd8, thereby leading to stabilisation of the CRL substrate 
p27. 
 
CRLs constitute the largest family of E3 ubiquitin ligases, primarily due 
to their modular structure. There are six different Cullin homologous proteins, 
with each forming a scaffold onto which different E3 ligase complexes 
assemble (Petroski and Deshaies, 2005; Bosu and Kipreos; 2008). CRLs bind 
the RING subunit at the carboxy-terminus, which functions to recruit the 
ubiquitin-charged E2 ubiquitin-conjugating enzyme. At the amino-terminus, 
CRLs bind different substrate receptors, which are responsible for recruiting 
specific cellular substrate proteins. As a result of the assembly, the substrate 
is brought into close proximity to the ubiquitin-charged E2 enzyme, thus 




However, CRL-dependent ubiquitination of substrate proteins requires 
modification of CRL by the 76-amino acid ubiquitin-like protein Nedd8. Nedd8 
conjugation to a conserved lysine residue in the carboxy-terminus of CRLs 
induces a conformational change in CRL that is required to activate its 
ubiquitination activity. 
 
1.3 Cif functions as a deamidase 
Recent studies have revealed that Cif functions as a deamidase that 
targets Nedd8 on Gln40, thus converting it into a glutamate (Cui et al., 2010) 
(Figure 1 and 2). Mechanistically, it has been shown that Nedd8 deamidation 
does not preclude the conjugation of Nedd8 onto the Cullin protein, but 
prevents the Nedd8 induced conformational change of the CRL complex (Boh 
et al., 2011; Yu et al., 2015). Consequently, the Cif-mediated enzymatic 
modification in Nedd8 results in a marked inhibition of CRL activity, thus 
preventing ubiquitination of substrate proteins by CRLs and leading to 
stabilization of p21, p27 and other CRL substrates. Hence, the cell cycle 
inhibitory effect of Cif is attributed to Cif-dependent inhibition of CRL activity 





Figure 2. Cif deamidates Nedd8, thereby leading to inhibition of the NF-κB 
mediated host cell anti-bacterial defense. 
 
1.4 Aim of this project 
In my Honours project, I discovered that apart from CRL inhibition, Cif 
also exerts additional effects in host cells. Specifically, I found that Cif induces 
a potent and selective activation of the pro-survival ERK MAPK pathway. The 
goal of this project was hence to characterise the mechanism through which 
Cif activates ERK and address the potential significance and physiological 









2. MATERIALS AND METHODS 
Cell culture and transfection 
HEK293T cells were cultured in Dulbecco’s modified eagle medium 
(DMEM) (Invitrogen) supplemented with 10% (vol/vol) heat-inactivated fetal 
bovine serum (Hyclone), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin 
and 100 μg/ml streptomycin (Invitrogen) in a humidified 37°C, 5% CO2 tissue 
culture incubator. Transient transfections were performed using Genejuice 
transfection reagent (Novagen) in accordance with the manufacturer’s 
directions for sub-confluent cells. MLN4924 was a gift from Millennium 
Pharmaceuticals, Inc.  
 
Plasmid constructs 
The FLAG- or V5-B. pseudomallei Cif plasmids bearing an N-terminal 
2X FLAG or V5 epitope tag sequence used were previously described [12]. B. 
pseudomallei Cif C156S catalytic mutant (V5-Cif C156S) was generated via 
site-directed mutagenesis using forward primer 5’-GAT GAC GCC CGT GTC 
CGG ACT TTC GGC CA-3’ and reverse primer 5’-TGG CCG AAA GTC CGG 
ACA CGG GCG TCA TC-3’, and cloned into pcDNA3.1 with 5’ KpnI and 3’ 
XbaI and verified by DNA sequencing.  
FLAG-BimEL plasmid was a kind gift from Dr. Ong Sin Tiong. pBabe-
Puro-MEK-DD and pBabe-Puro-B-RAF-V600E were gifts from William Hahn 
(Addgene plasmid # 15268 and # 15269 respectively). The FLAG-WT HRas 
and FLAG-G12V HRas plasmids were generated by amplification from 




Karel Svoboda, Addgene plasmid # 18662 and # 18666, respectively) and 
cloned into pcDNA3.1 with 5’ KpnI and 3’ XbaI as described above. FLAG-
S17N HRas, dn SH2, SH3N (N-terminal SH3 domain) and SH3C (C-terminal 
SH3 domain) Grb2-HA plasmids were generated via site-directed 
mutagenesis and verified by DNA sequencing. FLAG-mSOS1 plasmid was a 
kind gift from Dr. Low Boon Chuan. FLAG-mSOS1 truncation mutants were 
generated by PCR through sequential C-terminal truncations.  
To generate S1164A/S1196A and S1164D/S1196D SOS1 mutants, I 
used gene synthesis (ShineGene Molecular Biotech, Inc.) and ordered the 
mouse SOS1 gene sequences between an internal AatII restriction site 
(nucleotide 3433) and the stop codon, including nucleotide substitutions that 
result in the S1164A/S1196A and S1164D/S1196D mutations (sequences as 
indicated in Figure 3). The two synthesised gene sequences were inserted 
into the FLAG-SOS1 pcDNA3.1 plasmid using the internal AatII restriction site 





Figure 3. Generation of mouse SOS1 S1164A/S1196A and S1164D/S1196D 





Cells were washed with ice-cold Phosphate-Buffered Saline (PBS) and 
then lysed in Triton X-100-containing lysis buffer. The composition of the lysis 
buffer was as follows: 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2.5 mM EDTA, 
2.5 mM EGTA, 20 mM NaF, 1 mM Na3VO4, 20 mM Sodium β-
Glycerophosphate, 10 mM Sodium Pyrophosphate, 0.5% Triton X-100, Roche 




precleared by centrifugation before use for Western blotting. Equal amounts of 
protein were loaded for Western blot analysis. All the following antibodies 
used were obtained from Cell Signaling Technology: anti-phospho-p38 
(Thr180/Tyr182), anti-p38, anti-phospho-SAPK/JNK (Thr183/Tyr185), anti-
SAPK/JNK, anti-phospho-ERK1/2 (Thr202/Tyr204), anti-ERK1/2, anti-Mcl-1, 
anti-phospho-Bad (Ser112), anti-Bad, anti-phospho-MEK1/2, anti-MEK1/2, 
anti-Grb2, anti-phospho-Akt (Thr308), anti-Akt, anti-phospho-STAT3 (Tyr705), 
anti-STAT3, except for anti-p27 (BD Biosciences), anti-HIF-1α (BD 
Biosciences), anti-α-tubulin (Molecular Probes), anti-β-actin (Sigma), anti-
FLAG M2 (Sigma), anti-V5 (Serotec) and anti-HA (Roche). All Western blots 
shown are representative of two independent experiments. 
 
Immunoprecipitation 
20 μl of anti-FLAG M2 agarose beads (Sigma) was used for 
immunoprecipitation. 500 μl of precleared lysate from cells transfected with 
FLAG-mSOS1 + empty vector or FLAG-mSOS1 + V5-Cif in 60-mm tissue 
culture dishes was added to the agarose beads. Untransfected cell lysate was 
added to control beads. The samples were tumbled for 1 hour at 4°C, and the 
beads were then washed four times in ice-cold NP40 lysis buffer (containing 
50 mM NaCl, 0.5% NP-40, 5% glycerol, 0.5 mM EDTA, 50 mM Tris, pH 7.5) 
and once in ice-cold buffer containing 50 mM Tris (pH 7.5). The 
immunoprecipitated mSOS1 proteins were then eluted and denatured in 2X 
Laemmli sample buffer (Biorad) containing 5% β-Mercaptoethanol and 





3.1 Stabilisation of CRL substrates by Cif is dependent on its catalytic 
activity 
It has been described that Cif catalyses the deamidation of NEDD8, 
and results in the stabilisation of CRL substrates such as p21 and p27 (Cui et 
al., 2010). Hence, in my Honours project, I first confirmed this report by 
examining the effect of Cif on the cellular abundance of some CRL substrates 
including p27 and HIF-1α in mammalian cells. I performed transient 
transfection of cif plasmid that was amplified from B. pseudomallei strain 
K96243 (Boh et al., 2011) in HEK 293T cells. MLN4924, the NEDD8 E1-
activating enzyme inhibitor, was used as a positive control (Soucy et al., 
2009). As shown in Figure 4A, Cif induced a marked accumulation of CRL 
substrates p27 and HIF-1α compared to the empty vector transfected cells. In 
contrast, Cif did not affect the stability of the non-CRL proteasome substrates 
cyclin B1 and geminin (Figure 4B). Similar to Cif transfected cells, MLN4924 
treated cells also showed an increase in p27 and HIF-1α protein levels, but 
notably to a lesser extent than the effect of Cif. Therefore, Cif was shown to 
be more potent than MLN4924 in stabilising the CRL substrates p27 and HIF-
1α. 
To further validate that CRL substrate stabilisation by Cif is dependent 
on its deamidase activity, I constructed a catalytically inactive cif mutant as 
described by Yao et al. (2009). Using site-directed mutagenesis, I mutated the 
critical cysteine residue at position 156 in the catalytic domain to serine. As I 




expressed in cells, no significant difference in the cellular abundance of p27 
was detected compared to control cells, whereas the wild type Cif was 
capable of inducing p27 accumulation (Figure 4C). This confirmed that the 
catalytic activity of Cif is indeed required to inhibit CRL function. When this 




Figure 4.  Effect of Cif on CRL substrates stabilisation. HEK 293T cells were 
transfected with B. pseudomallei Cif expression plasmids (either FLAG-tagged Cif or 
V5-tagged Cif or Cif C156S) for 48 hours and treated with 1 μM MLN4924 for the last 
24 hours. Cell lysates were resolved using SDS-PAGE and cellular abundance of 






3.2 Cif increases ERK MAPK phosphorylation in a manner dependent on 
its deamidase activity but independent of CRL inhibition 
In my efforts to discover mechanisms of action of Cif that are 
independent of CRL inhibition, I observed that Cif has a potent activating 
effect on the ERK pathway (see Figure 5B). Therefore, I sought to determine 
the exact molecular target and mechanism of action of Cif in regulating ERK 
activity. I first determined if Cif exhibits a preference for activating the ERK 
pathway compared to the p38 or SAPK/JNK MAPK pathways. Ectopic 
expression of Cif using a FLAG- or V5-epitope tagged Cif plasmid in HEK 
293T cells resulted in a marked induction of ERK1/2 phosphorylation. In 
contrast, Cif caused only a slight increase in p38 and SAPK/JNK 
phosphorylation (Figure 5A and B). This indicates that Cif selectively and 
potently activates the ERK MAPK pathway. 
 
Figure 5. Cif specifically increases ERK MAPK phosphorylation. (A, B) HEK 
293T cells were transfected with the indicated expression plasmids for 2 days, and in 
(B) treated with 1 μM MLN4924 for the last 24 hours. Pre-cleared cell lysates were 











































Cif has recently been reported to function as a deamidase, and its 
deamidase activity is dependent on its catalytic triad (Cui et al., 2010). Hence, 
I next sought to determine if the effect of Cif on ERK phosphorylation is 
dependent on its deamidase activity. To test this, I expressed a mutant of Cif 
in which the catalytic cysteine 156 residue in the triad is mutated to serine 
(C156S), in cells. As shown in Figure 5B, the catalytic inactive Cif mutant did 
not increase ERK1/2 phosphorylation, suggesting that ERK activation by Cif is 
dependent on its deamidase activity. It was noted that the expression level of 
the Cif mutant is not identical to that of wild type Cif. Hence, to confirm that 
the lack of effect of the Cif mutant is not due to the lower expression level, I 
performed a titration of the Cif mutant and measured the level of ERK 
activation. I found that a dose-dependent increase in the expression of the Cif 
mutant did not result in a corresponding increase in ERK activation (Figure 6). 
This further supports the finding that the Cif mutant is impaired in activating 
ERK, and that the effect of Cif on ERK activation is dependent on its 
deamidase activity. 
 
Figure 6. Cif increases ERK MAPK phosphorylation in a manner dependent on 
its deamidase activity. HEK 293T cells were transfected with the indicated 




transfected, with the lowest amount equal to that of V5-Cif expression plasmid. Cell 
lysates were analysed by Western blotting using the indicated antibodies. 
 
To date, the only known mechanism of action of Cif is to inhibit CRL 
activity via deamidation of its substrate Nedd8 (Cui et al., 2010). Therefore, I 
investigated whether the effect of Cif on ERK activation is a consequence of 
CRL inhibition. To test this, I used the CRL inhibitor MLN4924. MLN4924 
blocks the activation of Nedd8 by the Nedd8 E1-activating enzyme (Soucy et 
al., 2009). This prevents the transfer of Nedd8 onto CRLs and blocks the 
conformational change that is required to activate CRLs. As shown in Figure 
5B, when cells were treated with MLN4924, no increase in ERK activation 
was observed. This suggests that ERK activation is unlikely to be a 
consequence of CRL inhibition. To confirm this result, I used an alternative 
approach to inhibit CRL activity by employing a cell line that expresses a 
dominant negative mutant of the Nedd8 E2-conjugating enzyme Ubc12 
(dnUbc12). In this cell line, dnUbc12 expression is under control of a 
tetracycline-inducible promoter (Chew et al., 2007). Upon addition of 
tetracycline, dnUbc12 is induced and sequesters cellular Nedd8, thereby 
preventing endogenous Ubc12 from conjugating Nedd8 onto CRLs. As shown 
in Figure 7, expression of Cif resulted in a similar increase in ERK1/2 
phosphorylation in the absence and presence of tetracycline (lane 2 and 4). 
Thus, Cif causes marked ERK activation even when CRL activity is inhibited. 
Similarly, when Cif was expressed in the presence of the CRL inhibitor 
MLN4924, a further increase in ERK activity was observed (compare lane 6 to 




on ERK activity is independent of CRL inhibition, but dependent on Cif 
deamidase activity. Therefore, I hypothesised that Cif activates the ERK 
MAPK pathway via a target that is different from CRLs. 
 
Figure 7. Cif increases ERK MAPK phosphorylation in a manner independent 
of CRL inhibition. Tetracycline-inducible dominant negative Ubc12 HEK293 cells 
were transfected with FLAG-Cif expression plasmid for two days. Cells were then 
either treated with 1 μM tetracycline to induce dnUbc12 expression for the last 24 
hours or treated with 1 μM MLN4924 for the last 24 hours. Cell lysates were then 
analysed by Western blotting using the indicated antibodies. 
 
3.3 ERK activation confers a pro-survival signal through 
phosphorylation of the pro-apoptotic protein Bim 
It has been postulated that the inhibition of cell cycle progression as a 
result of Cif-dependent CRL inhibition slows down the turnover rate of 
epithelial cells (Kim et al., 2010; Taieb et al., 2011), thus promoting bacterial 
colonization of the lung epithelium. However, it is well known that prolonged 
CRL inhibition results in the accumulation of key cell cycle mediators and 




2011). The induction of apoptosis would self-limit B. pseudomallei infection. 
This raises the question of how the bacterium simultaneously inhibits host cell 
proliferation and prevents cell apoptosis. Therefore, I hypothesised that the 
physiological role of Cif in activating the pro-survival ERK MAPK pathway is to 
counter the pro-apoptotic effects of CRL inhibition. 
ERK is known to inhibit cellular apoptosis by regulating the 
phosphorylation status of the BH3 only protein Bim (Ley et al., 2005). 
Therefore, I examined whether Cif functions to modulate Bim phosphorylation. 
There are three major isoforms of Bim that are generated as a result of 
alternative splicing: Bim short (Bims), Bim long (BimL), and Bim extra long 
(BimEL) (Ley et al., 2005). BimEL has been reported to be the most abundant 
isoform. This isoform has also been shown to contain an ERK1/2 docking 
domain and ERK1/2 phosphorylation sites. Phosphorylation of BimEL by 
ERK1/2 targets it to the proteasome for degradation. Therefore, to test 
whether Cif counters the effect of the proapoptotic protein Bim, I expressed 
FLAG-tagged BimEL in the presence or absence of Cif and measured the 
phosphorylation of BimEL by western blot. I also used a known activator of 
ERK MAPK, active MEK (MEK-DD), as a positive control, as well as the MEK 
inhibitor U0126 as a negative control. As shown in Figure 8A, a band shift in 
BimEL was detected when FLAG-BimEL was co-expressed with Cif, compared 
to the empty vector control in the first lane. A similar band shift was also 
observed when FLAG-BimEL was co-expressed with MEK-DD. Cif- and MEK-




by Cif and MEK-DD was prevented through treatment with U0126 (Figure 8B). 
This indicates that Cif-induced BimEL phosphorylation is dependent on MEK.  
 
Figure 8. Cif regulates the expression of BimEL. (A) HEK 293T cells were co-
transfected with FLAG-BimEL and V5-Cif, MEK-DD or empty vector, or treated with 10 
μM U0126 for the last 6 hours. Cell lysates were then subjected to Western blotting 
using the indicated antibodies. (B) HEK 293T cells were co-transfected with FLAG-
BimEL and V5-Cif, MEK-DD or empty vector and treated with 10 μM U0126 for the 




Of note, I also observed that Cif expression increased the protein 
levels of anti-apoptotic Mcl-1 and promoted inhibitory phosphorylation of the 
pro-apoptotic Bad protein at Serine 112 (Figure 9). However, these effects of 
Cif were not inhibited by U0126 and were hence ERK1/2 independent. 
Moreover, inhibition of CRL activity with MLN4924 did not mimic the effects of 
Cif on Mcl-1 and Bad. Hence, the Cif induced increases in Mcl-1 protein 
expression and Bad Serine 112 phosphorylation are likely not due to CRL 
inhibition. Thus, when taken together my results suggest that Cif can exert 




























mechanisms. This may play a role to counter the pro-apoptotic effects of Cif 
dependent CRL inhibition. 
 
Figure 9. Cif regulates the expression or activity of apoptosis related proteins. 
HEK 293T cells were transfected with FLAG-Cif or empty vector and treated with 10 




3.4 Activation of the ERK MAPK pathway is independent of MAPK 
phosphatases but dependent on upstream kinases in the MAPK 
pathway 
Cif could potentially induce ERK1/2 phosphorylation via two 
mechanisms – by inhibiting MAPK phosphatases or by activating ERK or 
upstream MAP kinases. To first determine if Cif induces ERK activation by 
inhibiting the MAPK phosphatases, I treated cells with the phosphatase 
inhibitor okadaic acid and measured ERK phosphorylation in the presence or 




would be expected that Cif has less effect in cells in which MAPK 
phosphatases have been inactivated through okadaic treatment. However, as 
shown in Figure 10A, expression of Cif resulted in a similar increase in ERK 
phosphorylation in the absence and presence of okadaic acid. Thus, Cif 
increases ERK phosphorylation even when MAPK phosphatases are 
inhibited. This suggests that Cif-induced ERK activation is mediated via a 
mechanism that is different from MAPK phosphatase inhibition. 
However, in the experiment in Figure 10A, okadaic acid was only 
present during the last hour due to cytotoxic effects. Furthermore, I noted that 
okadaic acid treatment only resulted in a slight increase in ERK 
phosphorylation under basal conditions, suggesting that okadaic acid may not 
potently inhibit MAPK phosphatases (compare lane 3 to 1). Hence, to confirm 
that Cif activates the ERK pathway via a mechanism that is independent of 
MAPK phosphatase inhibition, I performed a chase experiment whereby I 
followed the rate of ERK dephosphorylation in the presence of the MEK 
inhibitor U0126. U0126 blocks the activity of phosphorylated MEK, thus 
rendering MEK unable to phosphorylate downstream ERK1/2. Hence, under 
these conditions, Cif would be expected to be unable to induce ERK1/2 
phosphorylation and could only increase ERK1/2 steady state phosphorylation 
levels by inhibiting the activity of a phosphatase that dephosphorylates ERK. 
In the experiment in Figure 10B, ERK1/2 phosphorylation was induced by 
transfecting cells with either Cif or constitutively active B-Raf-V600E. At time 
zero, cells were treated with U0126 to prevent further ERK1/2 




treatment with U0126 resulted in a decrease in ERK1/2 phosphorylation over 
time. In cells transfected with Cif, ERK1/2 dephosphorylation was not 
inhibited. This indicates that Cif does not function by inhibiting the activity of a 
phosphatase that dephosphorylates ERK. ERK1/2 phosphorylation did in fact 
decrease significantly faster in Cif-transfected cells compared to control cells. 
The reason for this is currently not clear. In summary, the results suggest that 




Figure 10. Cif activates ERK MAPK signaling in a manner independent of 
MAPK phosphatases but dependent on MAPK kinases. (A) HEK 293T cells were 
transfected with V5-Cif or empty vector and treated with 20 nM okadaic acid, 10 μM 
U0126 or 0.1% DMSO control for the last hour. Cells were then lysed and analysed 
by Western blotting using the indicated antibodies. (B) HEK 293T cells were 









































3.5 Cif targets the ERK MAPK pathway upstream of Ras and 
downstream of RTKs 
To elucidate the target of Cif in the ERK MAPK pathway, I took a 
systematic bottom-up approach. Thus, I examined if Cif directly activates a 
candidate kinase or a kinase that is upstream in the pathway by using a panel 
of kinase inhibitors (Figure 11A). In this pathway, ERK is a downstream target 
of the ERK kinase (MEK1/2). MEK1/2 is activated by an upstream 
serine/threonine kinase Raf. Raf is in turn regulated by the small GTPase 
Ras, which is an effector of the tyrosine kinase epidermal growth factor 
receptor (EGFR). I found that when cells were treated with the MEK inhibitor 
U0126, Cif-dependent ERK activation was completely prevented (Figure 9, 
Figure 10A – compare lane 6 to 2). U0126 blocks the ability of active MEK to 
phosphorylate ERK1/2. Therefore, the lack of effect of Cif on ERK 
phosphorylation in the presence of U0126 suggests that Cif does not directly 
activate ERK but functions upstream of the ERK kinase. 
I next determined whether Cif directly activates MEK or another kinase 
or signaling intermediate that is further upstream of MEK. I treated cells with 
the Raf inhibitor BAY 43-9006, which inhibits the kinase activity of C-Raf and 
B-Raf and thus blocks MEK and ERK phosphorylation. As shown in Figure 
11B, inhibition of Raf activity with BAY 43-9006 significantly inhibited 




that Cif directly activates MEK. This result indicates that Cif may mediate its 
effect on ERK activation via Raf or a target that is upstream of Raf. 
    
 
Figure 11. Cif likely activates Raf or a target that is upstream of Raf. (A) 
Schematic diagram of ERK/MAPK pathway. (B) HEK 293T cells were transfected 
with the indicated expression plasmids for two days and then treated with 10 μM 
BAY 43-9006 or 0.1% DMSO for the last 6 hours, followed by Western blotting of the 
cell lysates using the indicated antibodies. 
 
Therefore, to determine if Cif directly activates Raf, I used a dominant 
negative Ras mutant, S17N HRas, as an approach to inhibit Ras activity. It is 
generally accepted that S17N HRas exerts its effects by sequestering 
upstream activators and simultaneously being impaired in activating 
downstream effectors (Nassar et al., 2010). As a result, S17N HRas inhibits 
the activation of endogenous Ras and prevents downstream Ras signaling 
events. When I expressed FLAG-tagged S17N HRas, I observed that the 































(Figure 12 – compare lane 4 to 2). This result suggests that Cif functions at 
the level of Ras or upstream of Ras to mediate its effect on ERK activation. 
  
Figure 12. Cif likely activates ERK MAPK signaling at the level of Ras or 
upstream of Ras. HEK 293T cells were transfected with the indicated expression 
plasmids for two days, followed by Western blotting of the cell lysates using the 
indicated antibodies. 
 
The dominant negative Ras functions by sequestering the upstream 
Grb2-SOS1 complex. This suggests that ERK activation by Cif is dependent 
on a functional Grb2-SOS1 complex. In response to RTK activation, the Grb2 
protein normally recruits SOS1 to the plasma membrane. Upon plasma 
membrane translocation, SOS1 can activate plasma membrane-bound Ras by 
functioning as a guanine nucleotide exchange factor (GEF) for Ras. 
Therefore, we next tested whether Cif requires plasma membrane 
translocation of the Grb2-SOS1 complex to activate ERK. To test this, I used 
dominant negative mutants of Grb2 that prevent the recruitment of SOS to the 
plasma membrane (Tanaka et al., 1995; Gupta and Mayer, 1998). The Grb2 







































and the other at the C-terminus of Grb2. The SH3 domains mediate the 
binding to a proline-rich region in SOS. The Grb2 protein also contains one 
Src Homology 2 (SH2) domain that is responsible for binding to specific 
phosphorylated tyrosine residues on activated RTKs. In our experimental 
approach, I used dominant negative SH2 and SH3 Grb2, in which the SH2 
domain and the SH3 domains in Grb2 are inactivated by point mutations, 
respectively. Dn SH2 Grb2 is expected to bind to endogenous SOS1, but is 
unable to recruit SOS1 to RTKs. Hence, dn SH2 Grb2 sequesters SOS1 in the 
cytoplasm. In contrast, dn SH3 Grb2 is expected to bind to RTKs but not to 
SOS1. Consequently, dn SH3 Grb2 prevents binding of the endogenous 
Grb2-SOS1 complex to RTKs. As shown in Figure 13, when I co-expressed 
dn SH3N Grb2 (N-terminal) or dn SH3C Grb2 (C-terminal) with Cif, Cif-
induced ERK activation was markedly inhibited, as indicated by the 
pronounced decrease in ERK phosphorylation (compare lane 6 or 8 to lane 
2). This result suggests that the effect of Cif on the ERK MAPK pathway is 





Figure 13. Cif-induced activation of MAPK/ERK signaling is dependent on a 
functional Grb2-SOS1 complex. HEK 293T cells were transfected with the 
indicated expression plasmids for two days, followed by Western blotting of the cell 
lysates using the indicated antibodies. 
 
 
The dn SH2 Grb2 also inhibits the translocation of SOS1 to the plasma 
membrane. However, when I expressed dn SH2 Grb2, I only observed a slight 
inhibition of ERK activation by Cif (Figure 13, compare lane 4 to 2). It was 
noted, however, that compared to the dn SH3 Grb2 mutants, the expression 
level of dn SH2 Grb2 was lower. I thus tried to validate the dn Grb2 proteins 
by measuring their effects on growth factor-induced ERK1/2 activation. I found 
that dn SH3N Grb2 and dn SH3C Grb2 had a strong inhibitory effect, whereas 
dn SH2 Grb2 inhibited serum-induced ERK1/2 activation only weakly (Figure 
14). Hence, the effect of the various dn Grb2 constructs on growth factor-
induced ERK1/2 activation correlates well with their effects on Cif-induced 





































activated by Cif, presumably dependent upon the recruitment of the Grb2-
SOS1 complex to the plasma membrane. 
 
 
Figure 14. Effect of dominant negative Grb2 proteins on growth factor-induced 
ERK1/2 activation. HEK 293T cells were transfected with the indicated expression 
plasmids for two days. The cells were then incubated for 6.5 hours in serum free 
medium, followed by re-addition of serum for 30 min, where indicated. The cell 
lysates were then analysed by Western blotting using the indicated antibodies. 
 
My results in Figure 13 raise the possibility that Cif functions by 
mediating RTK activation. To test this possibility, I examined the effect of Cif 
on the PI3K/Akt pathway, which is also downstream of RTKs. I found that Cif 
had no effect on the PI3K/Akt pathway as indicated by a lack of an increase in 
Akt phosphorylation at threonine 308 (Figure 15A). It is also known that 
growth factor signaling via RTKs can lead to the activation of the STAT3 
pathway. However, I found that Cif transfection did not lead to STAT3 
activation, as indicated by the lack of an increase in STAT3 phosphorylation 




constitutively active Ras (G12V HRas) (Figure 15B). These results indicate 
that Cif does not directly activate RTKs and suggest that Cif targets the Grb2-
SOS1 complex downstream of RTKs to activate the ERK MAPK pathway. 
 
Figure 15. Cif likely activates ERK MAPK signaling at the level of the Grb2-
SOS1 complex. (A, B) HEK 293T cells were transfected with the indicated 
expression plasmids for 2 days, and then treated with 1 μM MLN4924 (A) for the last 





3.6 Cif expression modifies SOS1 in a region containing the CDC25-H 
and proline-rich domains	  
My results suggest that Cif exerts its effects on the ERK MAPK 
pathway downstream of the RTKs, and that it potentially acts at the Grb2-
SOS1 complex. Hence, I sought to characterise the potential mechanism 
through which Cif modifies the Grb2-SOS1 complex to activate ERK MAPK. 




activity in SOS1 to catalyse GDP to GTP exchange in Ras (Groves and 
Kuriyan, 2010). I hence hypothesised that Cif increases Grb2-SOS1 binding to 
promote SOS1 activity. Therefore, I examined the binding of Grb2 to SOS1 in 
the presence or absence of Cif by using co-immunopreciptation. As shown in 
Figure 16, I was able to readily detect an interaction between transfected 
FLAG-SOS1 and endogenous Grb2. However, I found that there was no 
noticeable difference in the amount of Grb2 that was co-immunoprecipitated 
with SOS1 when Cif was present. This suggests that Cif does not alter Grb2-
SOS1 binding to promote SOS1 activity. However, interestingly, I noted that 
the co-expression of SOS1 and Cif resulted in a slight band shift in SOS1 as 
seen in both the lysate and the FLAG IP lanes (Figure 16), suggesting that Cif 
may possibly induce SOS1 phosphorylation. 
 
Figure 16. Cif does not alter Grb2-SOS1 but decreases mSOS1 mobility. HEK 
293T cells were transfected with the indicated expression plasmids for two days, 
followed by FLAG immunoprecipitation from the cell lysates using FLAG-agarose, 
and subsequently Western blotting using the indicated antibodies.	  
 
The Ras guanine nucleotide exchange factor SOS1 has a multi-domain 




domain, a Dbl homology (DH)-Pleckstrin homology (PH) domain, a Ras 
exchanger motif (REM), a CDC25-homology (CDC25-H) domain with GEF 
activity, and a proline-rich C-terminal region that binds Grb2 and links SOS1 
to activated RTKs. The catalytic REM and CDC25-H domains govern the GEF 
activity of SOS1 on its target Ras protein. The histone fold domain and the 
DH-PH domain have been suggested to exert an auto-inhibitory effect on the 
catalytic REM and CDC25-H domains (Corbalan-Garcia et al., 1998; Rojas et 
al., 2011). It is also known that the C-terminal proline-rich region of SOS1 
contains multiple phosphorylation sites that possibly play a role in the 
regulation of Ras activation by SOS1 (Douville and Downward, 1997).  
Given the key role of these domains in the regulation of SOS1 function, 
I therefore hypothesised that Cif modulates the phosphorylation status of one 
of these domains to contribute to increased ERK activation. To investigate 
and map the phosphorylation sites, I generated a number of mouse SOS1 
(mSOS1) C-terminal deletion constructs comprising amino acids 1-1230, 1-
757, and 1-574. I then co-expressed each deletion mutant with Cif to examine 
which region of SOS1 is responsible for the band shift in the presence of Cif. I 
found that only the mSOS1 (a.a 1-1230) mutant retained the band shift pattern 
similar to full length mSOS1 with Cif co-expression (Figure 17). In contrast, all 
other deletion constructs showed no band shift in the presence of Cif. This 
suggests that Cif likely modulates the phosphorylation status of mSOS1 in the 







Figure	  17.	  Cif	  expression	  regulates	  the	  CDC25-­‐H	  and	  proline-­‐rich	  domains	  in	  SOS1.	  
HEK 293T cells	   were	   transfected	   with	   the	   indicated	   FLAG-­‐mSOS1	   truncation	  
constructs	  for	  two	  days,	  followed	  by	  Western	  blotting	  using	  the	  indicated	  antibodies.	  
The	  blot	   in	   the	   second	  panel	  was	  obtained	   from	  running	  a	  duplicate	   set	  of	   lysates	  
through	  another	  SDS-­‐PAGE	  gel	  of	  a	  lower	  resolving	  power.	  
 
 
To confirm that the Cif-induced slower migration of SOS1 is indeed due 
to phosphorylation, I used phosphatase treatment. In this approach, cell lysate 
was incubated with Calf Intestinal Alkaline Phosphatase (CIP) followed by 
SDS-PAGE and Western blotting to determine if the SOS1 mobility shift can 
be reversed. To validate this approach, I initially confirmed dephosphorylation 
of the known phosphoprotein FRAT1. As shown in Figure 18, transfected 
FRAT1-FLAG exhibits both basal phosphorylation (as indicated by the smear 




by co-expression of GSK3β (see the mobility shift in lane 2). Both basal and 
GSK3β induced FRAT1 phosphorylation were reversed after incubation of the 
cell lysates with CIP. 
 
 
Figure 18. CIP-mediated FRAT1 dephosphorylation. HEK 293T cells were 
transfected with FRAT1-FLAG and GSK3β-V5 expression plasmids, as indicated. 
After two days, cells were lysed using triton X-100 lysis buffer that did not contain 
phosphatase inhibitors. Cell lysates were incubated with Calf Intestine Alkaline 
Phosphatase (CIP) (New England Biolabs) for one hour at 37°C (20 μl cell lysate with 
or without 20 units CIP). The reaction was stopped by adding 2xSDS loading buffer 
and the samples were analysed by SDS-PAGE and Western blotting. (NB: 
Transfected GSK3β-V5 in lanes 2 and 4 has a slightly increased size compared to 
endogenous GSK3β due to the presence of the V5 epitope tag.) 
 
 
I then co-expressed SOS1 with or without Cif and determined if 
incubation of cell lysate with CIP was able to reverse the Cif-induced 
bandshift. However, in contrast to FRAT1, CIP did not reverse the bandshift of 
SOS1 (Figure 19). I also used Shrimp Alkaline Phosphatase, which was 
similarly unable to increase SOS1 mobility (data not shown). These results 
suggest that the Cif-induced phosphorylation sites are not dephosphorylated 
by Alkaline Phosphatases or alternatively that Cif induces a different type of 
post-translational modification in SOS1. However, these results also do not 




modification because not all phosphorylated sites are sensitive to calf 
intestinal or shrimp alkaline phosphatases. 
 
 
Figure 19. CIP-dependent SOS1 dephosphorylation. HEK 293T cells were 
transfected with FLAG-SOS1 and V5-Cif expression plasmids, as indicated. Cell lysis 
and Calf Intestine Alkaline Phosphatase (CIP) incubation were performed as 
described in Figure 5C. Lanes 1 and 2 correspond to the original lysates before the 
incubation at 37°C with or without CIP. 
 
Therefore, I subsequently used an alternative mass spectrometry-
based approach to determine whether Cif induces phosphorylation or other 
post-translational modifications in SOS1. Thus, I transfected three 15 cm-
diameter petri dishes each with FLAG-mSOS1 with or without V5-Cif. Cells 
were then lysed and subjected to FLAG-immunoprecipitation. The FLAG 
immunoprecipitates were run on a 10% SDS-PAGE gel and the Coomassie-
stained FLAG-mSOS1 bands (Figure 20) were excised, subjected to in-gel 
trypsin digestion and submitted for LC-MS/MS analysis by the NUS Protein 
and Proteomics Centre (PPC). The detected mSOS1 tryptic peptides were 
then analysed for differences in phosphorylation or other post-translational 





Figure 20. SOS1 immunopurification for mass spectrometry analysis. HEK 
293T cells were transfected with the indicated expression plasmids for two days, and 
the cells were then lysed and subjected to FLAG-immunoprecipitation. The FLAG 
immunoprecipitates were run on a 10% SDS-PAGE gel (duplicate lanes for each 
sample), followed by staining of the gel using Coomassie Brillant Blue R-250. The 
FLAG-mSOS1 duplicate bands were excised and pooled together respectively, and 
subjected to in-gel trypsin digestion. The tryptic peptides were then analysed using 
LC-MS/MS by the NUS PPC. Shown here is a Coomassie gel image representative 





Table 1. Phosphorylation status of mSOS1 in the presence or absence of Cif. 
Phosphorylation sites detected in LC-MS/MS are indicated in red. Two candidate 
phosphorylated serine residues Ser1164 and Ser1196 (highlighted in green) showed 
higher tendency to be phosphorylated in the presence of Cif compared to in the 



















LPGASSAEYR S484 1/22.(5%) 1/15.(7%)
IPESETESTASAPNSPR S1082 3/6.(50%) 5/40.(13%)
TPLTPPPASGTSSNTDVCSVFDSDHSASPFHSR T1088 1/11.(9%) 4/14.(29%)
SASVSSISLSK S1120 3/16.(19%) 4/17.(24%)
SASVSSISLSK S1123 1/16.(6%) A
RPESAPAESSPSKIMSK S1152 1/24.(4%) 4/21.(19%)
R(RPESAPAESSPSKIMSK) S1153 19/24.(79%) 12/21.(57%)
HLDSPPAIPPR(QPTSK) S1164 40/50.(80%) 19/62.(31%)
TSISDPPESPPLLPPR(EPVR) S1196 24/28.(86%) 11/61.(18%)
TPDVFSSSPLHLQPPPLGK S1213 A 2/72.(3%)
TPDVFSSSPLHLQPPPLGK S1215 8/28.(29%) 1/72.(1%)
K(SDHGNAFFPNSPSPFTPPPPQTPSPHGTR)(R) T1249 A 1/18.(6%)
K(SDHGNAFFPNSPSPFTPPPPQTPSPHGTR) S1251 1/12.(8%) 3/18.(17%)
R(HLPSPPLTQEM)(DLHSIAGPPVPP)(R) S1261 32/39.(82%) 34/53.(64%)





MS/MS output shown in this table are representative of 2 separate 
experiments. “-“: refers to no tryptic peptides detected. “()”: refers to trypsin 
cut sites. 
 
We identified two amino acids in mouse SOS1, Ser1164 and Ser1196, 
which showed increased phosphorylation in the presence of Cif. These 
residues are conserved in human SOS1 (Figure 21). Interestingly, these two 
serine residues are immediately proximal to two of the four proline-rich 
PxxPxR motifs in SOS1 (Figure 21). These motifs are involved in binding of 
SOS1 to the SH3 domain of Grb2, although a recent report found that they are 
not required for SOS1 interaction with Grb2 in vivo (Bartelt et al., 2015). Both 
of these serines in human SOS1 have been previously identified in a large-
scale phosphoproteomics study and found to be phosphorylated residues 
(Zhou et al., 2013). However, there are no reports on the functional role of the 
phosphorylation of Ser1164 and Ser1196 or Ser1178 and Ser1210 in mouse 





Figure 21. C-terminal amino acid sequence of mouse and human SOS1. The 
identified Cif-induced phosphorylation sites are indicated in red and the PxxPxR 
motifs in SOS1 in bold. 
 
3.7 Characterisation of the identified Cif-induced phosphorylation sites 
on SOS1 
In order to characterise the functional significance of the Cif induced 
phosphorylation of SOS1 at Ser1164 and Ser1196, I generated a double 
mutant in which both serine residues were substituted with alanine, as 
described under Materials and Methods. I also generated an aspartate double 





I first determined whether Cif induced SOS1 phosphorylation is 
prevented in the S1164A/S1196A mutant. Cells were transfected with wild 
type or mutant SOS1 with or without co-transfection of Cif. As shown in Figure 
22, co-transfection of Cif induces an obvious decrease in wild type SOS1 
mobility. When Cif was co-transfected with S1164A/S1196A mutant SOS1, 
the mobility shift was reduced. This result confirms that Cif induces SOS1 
phosphorylation of Ser1164 and Ser1196 and suggests that phosphorylation 
of Ser1164 and/or Ser1196 is partially responsible for the observed slower 
migration of SOS1 when Cif is expressed. 
I also determined whether expression of the non-phosphorylatable 
S1164A/S1196A SOS1 mutant inhibits Cif-dependent ERK1/2 activation. As 
shown in Figure 22, S1164A/S1196A mutant SOS1 was without effect on 
ERK1/2 activation by Cif. 
 
 
Figure 22. Characterisation of the identified Cif-induced phosphorylation sites 
on SOS1. HEK 293T cells were transfected with the indicated expression plasmids. 




note that in the FLAG Western blot the “S1164A/S1196A SOS1, without V5-Cif” 
sample was run twice to better visualise the Cif-induced mobility shift. 
 
I finally determined whether expression of the S1164D/S1196D SOS1 
mutant mimics Cif-dependent ERK activation. To this end, I transfected cells 
with empty vector, wild type, S1164A/S1196A or S1164D/S1196D mutant 
SOS1 and determined the effect on ERK1/2 activity. As shown in Figure 23, 
overexpression of wild type SOS1 increased ERK1/2 phosphorylation. The 
S1164A/S1196A mutant had a similar effect on ERK1/2 phosphorylation 
compared to wild type SOS1. The S1164D/S1196D mutant did not further 
increase ERK1/2 activity compared to the effect exerted by wild type SOS1. 
This suggests that the S1164D/S1196D is unable to mimic the effect of Cif on 
the MAPK/ERK pathway. Taken together, the results indicate that Cif indeed 
induces the phosphorylation of SOS1 at Ser1164 and Ser1196. However, a 





Figure 23. Effect of overexpression of wild type and mutant SOS1 on ERK1/2 
phosphorylation. HEK 293T cells were transfected with the indicated expression 
plasmids. Two days after transfection, cells were lysed and cell lysates were 















4. DISCUSSION 	  
Cif has previously been shown to inhibit CRL function (Cui et al., 2010). 
CRL inhibition is due to a novel mechanism that involves a unique 
deamidation of Nedd8, which is a ubiquitin-like protein that is conjugated to 
cullin proteins and necessary for CRL activation. Here I provide evidence for a 
novel function of Cif that is independent of CRL inhibition but dependent on its 
deamidase activity. I found that Cif expression induces marked ERK 
phosphorylation and thus leads to the activation of ERK MAPK signaling, 
indicating that Cif has an effect on cellular signaling. Importantly, my results 
suggest that Cif deamidase likely has other downstream targets in addition to 
Nedd8. 
My results suggest that Cif acts at the level of SOS1 via a novel 
mechanism that potentially involves SOS1 phosphorylation. Thus, Cif caused 
slower mobility of SOS1 and SOS1 deletion analysis suggested that this effect 
is mediated via a region in SOS1 that comprises the CDC25-H and proline-
rich domains. Protein deamidation has been found to cause an increase in 
protein mobility in native gels, but is without effect on protein migration in SDS 
gels (Cui et al., 2010). Hence, the observed SOS1 mobility change upon Cif 
co-expression is most likely due to one or more phosphorylation events. To 
confirm this, I used phosphatase treatment of lysates from SOS1 and Cif 
expressing cells. However surprisingly, treatment with calf intestine alkaline 
phosphatase or shrimp alkaline phosphatase was unable to reverse the 
slower migration of SOS1. A positive control experiment indicated that FRAT1 




observed mobility change in SOS1 is due to a protein modification different 
from phosphorylation or deamidation. Alternatively, it is possible that the Cif-
induced phosphorylation site(s) in SOS1 are resistant to alkaline phosphatase 
treatment. 
To distinguish between the different possibilities that might be 
responsible for the SOS1 mobility change, we analysed SOS1 post-
translational modifications by mass spectrometry. Full length SOS1 was 
isolated from cell lysates after expression of FLAG-mSOS1 in the absence or 
presence of Cif. Three repeat experiments were performed and detailed 
analysis of the detected tryptic peptides showed a great number of 
deamidation and phosphorylation sites in the mouse SOS1 protein. However, 
only two sites, Ser1164 and Ser1196, showed a consistent Cif-dependent 
increase in phosphorylation. Importantly, based on the mSOS1 deletion 
construct experiments, these two residues are located in the region of Cif that 
is responsible for the Cif-induced mobility change. Of note, the corresponding 
two serine residues in human SOS1 have been previously identified in a 
large-scale phosphoproteomics study to be phosphorylated (Zhou et al., 
2013). However, so far there are no reports on the functional role of these 
phosphorylation events. 
I then proceeded to confirm the Cif-dependent phosphorylation of 
Ser1164 and Ser1196 and characterise the functional significance by 
performing mutagenesis experiments. The S1164A/S1196A SOS1 mutant 
was at least partially resistant to Cif-induced phosphorylation. This indicated 




phosphorylation events and that these are at least partially accounted for by 
the phosphorylation of Ser1164 and Ser1196. 
It is very intriguing that the two phosphorylation sites are located at 
equivalent sites immediately upstream of two PxxPxR motifs in SOS1. 
Although these motifs are known to be involved in binding of SOS1 to the SH3 
domain of Grb2, I did not observe an effect of Cif expression on the interaction 
between SOS1 and Grb2. However, it would be interesting to determine 
whether the Ser1164 and Ser1196 SOS1 mutants generated in my study 
display altered binding to Grb2. 
I conducted further experiments using the mutants to determine 
whether the Cif-induced phosphorylation of SOS1 is functionally important for 
the regulation of MAPK/ERK signaling. I found that overexpressing the non-
phosphorylatable SOS1 S1164A/S1196A mutant did not prevent Cif-induced 
MAPK/ERK activation. However, this does not rule out that Cif-induced 
Ser1164 and Ser1196 phosphorylation is functionally significant as 
endogenous SOS1 was still expressed. In future work, it would hence be 
important to simultaneously transfect cells with siRNA targeting endogenous 
SOS1 and siRNA-resistant wild type and S1164A/S1196A mutant SOS1 
expression plasmids. This experiment would be expected to be more 
conclusive in determining the role of Cif-induced SOS1 phosphorylation in 
ERK activation. 
I also found that overexpression of the S1164D/S1196D mutant of 
SOS1 did not mimic MAPK/ERK activation induced by Cif. Mutation of serine 




similar downstream effects. However, it is important to note that this is not the 
case in every instance. Hence, a lack of effect of phosphomimetic mutants 
does not rule out a functional significance of a phosphorylation event. Taken 
together, although the experiments presented did not provide support for a 
role of Ser1164 and Ser1196 phosphorylation in Cif-induced MAPK/ERK 
activation, the results do not disprove such a role and further studies will be 
required. However, it is also possible that Cif induces the phosphorylation of 
other residues in SOS1 that were not detected in our proteomics study or 
activates MAP/ERK by inducing other post-translational modifications. 
The mechanism through which Cif alters SOS1 function is currently not 
clear. My experiments suggest that Cif causes modification of SOS1 in a 
region that comprises the CDC25-H and proline-rich domains. The CDC25-H 
domain, together with the REM domain, mediates Ras nucleotide exchange. 
The C-terminal region has been suggested to exert a negative regulatory 
effect on the activity of human SOS1 (Corbalan-Garcia et al., 1998; Kim et al., 
1998; Hall et al., 2002). Therefore, it is possible that by modifying these 
domains, Cif regulates SOS1 catalytic activity or alternatively downregulates 
or reverses the negative regulatory effects of the C-terminal region of SOS1. 
This would enhance the GEF activity of SOS1 and hence promote Ras 
activation and downstream signaling events. However, it is also possible that 
Cif functions to activate Ras via a different mechanism. 
Importantly, my results raise the interesting possibility of the existence 
of an upstream regulator of SOS1 that can lead to a marked activation of ERK 




found to mainly play a negative regulatory role on ERK MAPK signaling 
(Kamioka et al., 2010). Thus, identification of the mechanism underlying Cif-
dependent ERK MAPK activation is likely to provide novel insights into the 
regulation of this important signaling pathway. 
How Cif promotes the pathogenicity of B. pseudomallei is currently not 
well characterised. It was originally proposed that Cif promotes the 
intracellular bacterial replication by inhibiting the turnover of epithelial host 
cells (Kim et al., 2010). This effect is due to cell cycle arrest as a result of the 
Cif-mediated inhibition of CRL-mediated degradation of cell cycle inhibitors 
such as p27. However, in a recent paper by McCormack et al. (2015), it was 
demonstrated that during Yersinia pseudotuberculosis infection, Cif plays a 
role to inhibit the activity of perforin-2, a mediator of the innate immune 
response of host cells. The authors found that upon Y. pseudotuberculosis 
infection, perforin-2 becomes activated through monoubiquitination. Perforin-2 
ubiquitination is mediated via the CRL SCFβ-TrCP and this results in the 
translocation of perforin-2 to cellular membranes, in particular the plasma and 
endosomal membranes. Upon translocation, perforin-2 then exerts its 
bactericidal activity by inducing lysis of plasma membrane-bound or 
endosome-encapsulated bacteria. Importantly, the authors demonstrated that 
in vivo Cif increases Y. pseudotuberculosis virulence in wild type but not 
perforin-2 deficient mice. This indicates that inhibiting the perforin-2 





However, the described mechanism in Y. pseudotuberculosis infection 
is unlikely to be of major relevance during the infection with Cif-expressing B. 
pseudomallei. This is because B. pseudomallei can readily escape from the 
endosomes into the host cytosol (Stevens et al., 2002; Muangsombut et al., 
2008; Burtnick et al., 2008), thus avoiding the bactericidal activity of perforin-
2. As such, it is likely that perforin-2 does not play a major role in the 
response of host cells to B. pseudomallei infection. My study suggests an 
alternative mechanism through which Cif may potentially exert its cellular 
effect. Prolonged CRL inhibition is known to induce cellular apoptosis. This is 
partly due to prevention of the degradation of key cell cycle regulatory 
proteins, including the important DNA replication licensing factor CDT1. 
Failure to degrade CDT1 leads to DNA re-replication and induction of cellular 
apoptosis (Milhollen et al., 2011). Given that host cell apoptosis would also 
limit bacterial replication and survival, I hypothesised that Cif may counteract 
the pro-apoptotic effects of CRL inhibition by activating cellular anti-apoptotic 
pathways through ERK activation. I indeed observed that Cif expression 
increased the phosphorylation of the most abundant Bim splice variant BimEL 
in an ERK1/2-dependent manner. ERK1/2-dependent phosphorylation is well 
known to induce proteasome-dependent BimEL protein degradation. 
Surprisingly, despite inducing marked BimEL phosphorylation, Cif reduced the 
BimEL steady state protein levels only slightly. It may be necessary to carry out 
half-life measurements of endogenous BimEL protein to detect Cif-induced 
changes in BimEL protein stability. I also observed that Cif increased the 




leading to inhibition of its pro-apoptotic function (see Figure 4C). However, 
these effects were largely ERK independent as they were not or only slightly 
inhibited in the presence of MEK inhibitor. Interestingly, I also observed that 
expression of Cif could protect HEK293T cells from serum starvation-induced 
cell death (data not shown), suggesting that Cif-induced anti-apoptotic 
responses via the MAPK/ERK pathway are important. Hence, it would be of 
great interest to test whether Cif-dependent ERK MAPK activation and the 
induction of anti-apoptotic pathways is important to prevent host cell apoptosis 
and promote B. pseudomallei virulence in vivo. 
In conclusion, I have identified a novel deamidation-dependent 
mechanism of action of the B. pseudomallei virulence factor Cif to activate 
MAPK/ERK signaling. The elucidation of the exact molecular mechanism is 
expected to give important new insights into the regulation of the MAPK/ERK 
signaling pathway. My study demonstrates that bacterial proteins such as Cif 
can serve as useful molecular tools to uncover novel aspects of mammalian 
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